Medindia

X

Study Shows How Bone Marrow Transplantation Promotes Cancer Resistance in Patients

by Thilaka Ravi on  August 25, 2011 at 12:56 PM Organ Donation News   - G J E 4
Bone marrow transplantation with genetically modified cells may prolong the period of cancer-free survival, suggests a study led by Dr. Vivek Rangnekar, associate director of translational research for the Markey Cancer Center at the University of Kentucky.
Study Shows How Bone Marrow Transplantation Promotes Cancer Resistance in Patients
Study Shows How Bone Marrow Transplantation Promotes Cancer Resistance in Patients
Advertisement

Bone marrow, a spongy tissue inside bones, contains stem cells that produce blood cells, including leukocytes, erythrocytes and platelets. In the cover story of the July issue of Cancer Biology & Therapy, Rangnekar and his team explore the transfer of bone marrow from Par-4/SAC-transgenic donor mice to control mice as a means of transferring anti-cancer potential.

Advertisement
Par-4 (also known as PAWR) is a tumor suppressor protein that selectively induces apoptosis in cancer cells, but not normal cells. This function of Par-4 is mediated by its central core domain, SAC. SAC-transgenic mice are resistant to the growth of spontaneous and inducible tumors.

After transplantation, the researchers discovered the expression of cancer-killer SAC-GFP activity in bone marrow cells of the recipient mice, implying the successful transfer and colonization of the anti-cancer tissue from the donors. In addition, soluble Par-4 or SAC protein injected into mice inhibited the growth of metastatic tumors.

Rangnekar, the Alfred Cohen Endowed Chair of Oncology Research at Markey, says the study shows promise for treating both primary and metastatic tumors.

"We are excited by the findings of this study as they indicate that secreted Par-4 is systemically active in mice," Rangnekar said. "Optimization of the bone marrow transplantation procedure using stem cells that are genetically modified to systemically secrete potent protein payloads of Par-4/SAC killer activity may offer a new approach to treat not only primary tumors but also metastatic tumors of diverse origin."



Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All